Mankind Pharma posts Q2 FY25 PAT up 30% at Rs. 659 Cr
Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.
Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
He has more than 25 years of experience in manufacturing across various industries including petrochemicals, engineering polymers, agrochemicals, organic, and inorganic intermediates
Silica is a proven and highly effective anti-caking agent that has been used for decades
Subscribe To Our Newsletter & Stay Updated